Curida, Small Molecules and Biologics CDMO, Secures Private Equity Investment from Signet Healthcare Partners
Curida Holding AS (“Curida”) has announced a significant growth investment from Signet Healthcare Partners (“Signet”), a New York-based healthcare private equity firm. This strategic partnership will enable Curida to accelerate its expansion plans, including enhancing facility capabilities and growing its industry position.
Established in 2015 and headquartered in Oslo, Norway, Curida is an integrated Contract Development and Manufacturing Organization (“CDMO”) specializing in the use of blow-fill-seal (“BFS”) and nasal spray technologies, as well as antibody manufacturing. Curida provides outsourced development and manufacturing of aseptic and non-aseptic liquid BFS and nasal spray formatted drugs, and serves the diagnostics industry with monoclonal antibodies. Curida’s customer base ranges from small to medium-sized pharmaceutical, medical devices, and biotech companies, delivering solutions in drug development and GMP manufacturing globally.
In conjunction with Signet’s investment, Signet is joining the Board of Directors, and Ole J. Dahlberg has been appointed as Chairman of the Board. Dahlberg has more than 20 years of experience from leadership roles in the life science market and is former Vice President & General Manager at Thermo Fisher Scientific in California, USA. Dahlberg stated, “We are very pleased to welcome Signet as a significant shareholder in Curida. Signet brings strong relevant industry experience and a track record of CDMO investing. Signet is co-investing alongside Curida’s existing shareholders Canica, Investinor, Klaveness, and Farvatn. We are excited by the opportunity to further accelerate innovation and advance productivity for our pharma and biotech customers in their work to deliver medicines and therapeutics to benefit patients. On behalf of the board, I want to thank Per Thoresen, who has been acting Chairman of the Board and for his valuable contributions to Curida over the past 9 years.”
Additionally, the Board has appointed Anders Larsson, the Company’s Chief Operating Officer, as Chief Executive Officer, effective May 1st, 2024. Larsson comes with extensive experience in management, operations, and strategic development from the pharma industry. His former roles include CEO of Boots Pharmacy/Alliance Healthcare in Norway (Cencora). In addition, Larsson has experience from various roles in the food & beverage industry with Orkla and Carlsberg. Larsson holds an MSc in Chemical Engineering from Chalmers University and Imperial College and a BSc in Finance from Gothenburg University.
Signet Managing Director Nikhil Puri said, “We are proud to partner with Curida and support their robust growth strategy. The Company’s strong values, commitment to excellence, and strategic vision align nicely with our investment philosophy. We look forward to contributing to Curida’s success in the coming years. We were attracted to Curida due to its strong, differentiated manufacturing capabilities, customer-centric approach, and management team strength. We see a strong opportunity for Signet to leverage its network and prior CDMO investment experience to accelerate growth.”
DNB Markets served as financial advisor, and Advokatfirmaet Simonsen Vogt Wiig served as legal advisor to Curida. Sheppard, Mullin, Richter & Hampton LLP and Advokatfirmaet Selmer served as legal advisors to Signet. Terms of the transaction were not disclosed.
About Curida Group
Curida offers contract development and manufacturing solutions to European pharmaceutical and biotech companies globally. Curida focuses on aseptic and non-aseptic liquid manufacturing and specializes in blow-fill-seal (“BFS”) and nasal spray technologies to serve the Small Molecules pharmaceutical and medical device market. For biologics, Curida offers upstream- and downstream processing of monoclonal antibodies for in-vitro diagnostics (“IVD”). For more information, visit www.curida.no
About Signet Healthcare Partners
Headquartered in New York, NY, Signet is an established provider of growth capital to innovative healthcare companies. SIGNET invests in commercial-stage healthcare companies that are revenue generating or preparing for commercial launch. The firm invests primarily in pharmaceutical and medical device companies. As an active investor, Signet partners closely with its companies to build their value including facilitating activities between portfolio companies. During Signet's 25-year history, the firm has developed a strong reputation and track record of successful healthcare investments. Signet has raised funds with total capital commitments of over $600 million and has invested in more than 55 companies. For more information, visit www.signethealthcarepartners.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416093461/en/
Contact information
Curida Holding AS
post@curida.no
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
H.I.G. Capital Announces the Sale of DGS S.p.A.11.6.2024 12:00:00 CEST | Press release
H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $62 billion of capital under management, is pleased to announce that an affiliate has signed a definitive agreement to sell its portfolio company, DGS S.p.A. (“DGS” or the “Group”), a leading firm in the Italian Information Technology market, to DGS Co-Founders and management team in partnership with ICG, a global alternative asset manager. Since its inception in 1997, DGShas supported blue-chip customers in the design, integration, and maintenance of complex IT systems, with a specialization in digital transformation and cybersecurity services. The Group currently has over 1,900 employees, revenues of approximately €300 million, and maintains a group of highly loyal clientele. During H.I.G.’s ownership, DGS has tripled in size and consolidated its position as a leading Italian firm in cybersecurity services and digital transformation. DGS offers its clients sophisticated and proprietary digital transformation
Evertas Names Nick Selby Head of European Underwriting11.6.2024 12:00:00 CEST | Press release
Evertas, the world’s first crypto insurance company, has named Nick Selby as its new Head of European Underwriting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611141887/en/ Nick Selby, Executive Vice President and Head of European Underwriting at Evertas (Photo: Business Wire) Selby, an accomplished information and physical security professional, brings two decades of expertise in public and private sector information security, physical security, and complex incident handling, as well as seven years of experience leading teams securing billions of dollars in cryptoassets. Previously, his roles included VP of the Software Assurance Practice at Trail of Bits, Chief Security Officer at Paxos Trust Company, and Director of Cyber Intelligence and Investigations at the NYPD Intelligence Bureau. “Nick is an extremely valuable addition to our European team,” said Evertas CEO and Co-Founder J. Gdanski. “His public and private
Owlet utvider globalt fotavtrykk med lanseringen av medisinsk-sertifisert Dream Sock™ i Storbritannia og over hele Europa11.6.2024 11:00:00 CEST | Pressemelding
Owlet, Inc. («Owlet» or the «Company») (NYSE:OWLT), pioneren innen smart spedbarnsovervåking, kunngjør i dag den britiske og europeiske lanseringen av Dream Sock. Dette er en smart babymonitor med levende helseavlesninger og varsler for friske spedbarn mellom 0-18 måneder og 2,5-13,6 kg. Dette innovative medisinske utstyret gir foreldre helse og viktig informasjon i sanntid, noe som gir uovertruffen trygghet. Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: https://www.businesswire.com/news/home/20240611820341/no/ (Photo: Business Wire) «Vi er svært stolte over å lansere Dream Sock til omsorgspersoner over hele Storbritannia og Europa og gi millioner av foreldre mer trygghet mens babyen sover,» sa Kurt Workman, Owlets administrerende direktør og medgründer. «Dream Sock er nå et globalt produkt som er anerkjent som medisinsk nøyaktig og trygt, etter å ha gjennomgått regulatoriske autorisasjoner og sertifiseringer innenfor flere geografier. I dag er misjonen vår
V-Nova Surpasses 1000 Patent Milestone in Media Technology Innovation11.6.2024 10:00:00 CEST | Press release
V-Nova, a leading provider of data compression solutions, video compression technology, XR technology, AI acceleration and parallel processing for a multitude of industries including media and entertainment, today announced its milestone achievement of 1000 active technology patents. This accomplishment underscores V-Nova’s dedication to research and development and its commitment to protecting its intellectual property globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611724561/en/ V-Nova’s patent portfolio spans more than 50 different jurisdictions. Including over 400 patents in Europe, over 200 in the Americas, over 100 in the United States specifically, and over 200 in Asia. V-Nova forged new directions in data processing to enhance digital experiences, maximize efficiency, reduce costs, and increase sustainability. The company leads the way with key international data compression standards for the video indust
Alipay+ Reveals Top Scorer Trophy Design for UEFA EURO 2024™11.6.2024 09:24:00 CEST | Press release
Alipay+, a suite of cross-border mobile payment and digitalization technology solutions operated by Ant International and an Official Partner of UEFA EURO 2024™, today revealed the trophy that will be awarded to the most prolific marksman at the UEFA EURO 2024™ finale on July 14 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240610328619/en/ The UEFA Top Scorer Trophy presented by Alipay+ is unveiled for UEFA EURO 2024™ (Photo: Business Wire) Sculpted in the shape of the Chinese character “支” (pronounced zhi, and meaning payment as well as support), the trophy reflects Alipay+’s dedication to supporting consumers to enjoy seamless payment and a broad choice of deals using their preferred payment methods while traveling abroad. The character also resembles the fleeting moment of a barefooted striker poised to shoot, evoking the original beauty and power of football – a game that united people across the wo